Literature DB >> 12668155

Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect.

Yi Luo1, Xiaohong Chen, Michael A O'Donnell.   

Abstract

Induction of a T-helper-type 1 (Th1) immune response is indispensable for successful treatment of superficial bladder cancer with BCG. In this study possible involvement of various cytokines in BCG action as well as their potential roles in enhancing and mimicking BCG effect were explored. In immunocompetent cell cultures, IFN-gamma, a major Th1 cytokine, appears to be a late responsive cytokine to BCG stimulation. Its induction requires involvement of various endogenously produced Th1 and Th2 cytokines. Functional abolishment of any one of these cytokines (IL-2, IL-6, IL-12, IL-18, GMCSF, TNF-alpha, or IFN-alpha, except IL-10) by neutralizing antibodies leads to reduced IFN-gamma production (19-82% inhibition in mouse and 44-77% inhibition in human systems, respectively). In mice cytokines IL-2, IL-12, IL-18, and GMCSF are observed to synergize with BCG for IFN-gamma production, whereas in human cytokines IL-2, IL-12, TNF-alpha, and IFN-alpha exhibit similar synergistic effects. Rational combinations of these Th1-stimulating cytokines (IL-12 plus IL-18 in mice and IL-2 plus IL-12 in humans, respectively) dramatically up-regulate IFN-gamma production that is incomparably superior to BCG for induction of this cytokine. These results suggest that combined Th1-stimulating cytokines and combinations of BCG plus selected Th1-stimulating cytokines are rational candidates for further study in the treatment of bladder cancer patients. Copyright 2003 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668155     DOI: 10.1016/s1043-4666(02)00490-8

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  34 in total

1.  Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.

Authors:  Tomoko Hayashi; Brian Crain; Maripat Corr; Michael Chan; Howard B Cottam; Roberto Maj; Alcide Barberis; Lorenzo Leoni; Dennis A Carson
Journal:  Int J Urol       Date:  2010-03-11       Impact factor: 3.369

Review 2.  Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review.

Authors:  Elisa Tinazzi; Vincenzo Ficarra; Sara Simeoni; Walter Artibani; Claudio Lunardi
Journal:  Rheumatol Int       Date:  2005-10-12       Impact factor: 2.631

Review 3.  Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review.

Authors:  Daher C Chade; Shahrokh F Shariat; Guido Dalbagni
Journal:  Int Braz J Urol       Date:  2009 Nov-Dec       Impact factor: 1.541

Review 4.  Evolving immunotherapy strategies in urothelial cancer.

Authors:  Sam J Brancato; Keidren Lewi; Piyush K Agarwal
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

5.  Genetic susceptibility to bladder cancer risk and outcome.

Authors:  Jian Gu; Xifeng Wu
Journal:  Per Med       Date:  2011-05       Impact factor: 2.512

6.  Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Y Luo; R Han; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2010-02-10       Impact factor: 4.330

7.  Urinary bladder epithelium antigen induces CD8+ T cell tolerance, activation, and autoimmune response.

Authors:  Wujiang Liu; David P Evanoff; Xiaohong Chen; Yi Luo
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

8.  Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells.

Authors:  Y Luo; H Yamada; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

9.  Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.

Authors:  Y Luo; H Yamada; X Chen; A A Ryan; D P Evanoff; J A Triccas; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

10.  RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis model.

Authors:  Wujiang Liu; Barry R Deyoung; Xiaohong Chen; David P Evanoff; Yi Luo
Journal:  J Autoimmun       Date:  2007-12-26       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.